2015 BioPacific Conference Agenda
Theme: Opportunities, Challenges, and Growth – A New Era in Biomedical Innovation
May 9th, Saturday, 2015, San Mateo Marriott, 1770 South Amphlett Blvd., San Mateo, CA 94402
The official working language of the conference is English
| 8:00 – 9:00 am | Registration and Vendor Exhibition |
| 9:00 – 9:05 am | Opening Remarks Jiangwen Majeti, Ph.D./MBA, CABS President-elect & 2015 BioPacific Conference Organizing Committee Chair |
| 9:05 – 9:15 am | State of the Society Alan Hao, Ph.D., CABS President |
| 9:15 – 10:05 am | CABS K. Fong Award in Life Sciences & Keynote Speech
Award Winner: Dr. Irv Weissman |
| 10:05 – 12:20 pm | Developing Novel Therapies through Discovery and Technology Innovation Session chairpersons: Shichang Miao |
| 10:05 – 10:40 am | Allen Ebens, Ph.D., Senior Director of Research, Juno Therapeutics Adoptive Cell Therapies for Cancer: Challenges and Opportunities |
| 10:40 – 11:10 am | Coffee Break, Vendor Exhibition & Networking |
| 11:10 – 11:45 am | Jerry Shen, Ph.D., Executive Director of Biology, BioMarin Pharmaceutical Inc. BioMarin, a SF/Bay Area Growth Story |
| 11:45 am – 12:20 pm | Peter Staehr, Ph.D., Senior Director, Global Trials, Abbott Vascular Development of a coronary bioresorbable scaffold – The next revolution in Interventional Cardiology |
| 12:20 pm – 12:40 pm | Thomas Irving, J.D., Partner, Finnegan Developing U.S. Patents for Novel Therapies Through Discovery and Technology Innovations |
| 12:40 – 1:30 pm | Lunch |
| 1:30 – 2:50 pm | Celebrating Bay Area Biotech Industry Organic Growth Session chairpersons: Jiwen Liu |
| 1:30 – 2:00 pm | Jin-long Chen, Ph.D., Founder & Chief Scientific Officer, NGM Biopharmaceuticals, Inc. Building an “Old School” Biotech Company to Discover Novel Biological Medicines |
| 2:00 – 2:30 pm | Aaron Sato, Ph.D., Vice President of R&D, Sutro Biopharma Sutro Biopharma: A Bay Area Biotech Veteran that Reinvented Itself |
| 2:30 – 2:50 pm | Stephen Thau, JD, Partner, Morrison & Foerster LLP Status update for deals and financings in biotechnology |
| 2:50 – 3:15 pm | Platinum and Gold Sponsor Presentations |
| 3:15 – 3:45 am | Coffee Break, Vendor Exhibition & Networking |
| 3:45 – 5:00 pm | US/China Biomedical Science Funding Trend Session chairpersons: Howard Huang |
| 3:45 – 4:10 pm | Ming Zhao, Ph.D., Senior Director, SBIR Development Center, NCI NCI SBIR&STTR: Advancing the Commercialization of New Cancer Innovation |
| 4:10 – 4:35 pm | Darren Ji, Ph.D., Global Head/Vice President, Asia and Emerging Markets Partnering, F. Hoffmann-La Roche Maximizing the Capital Efficiency for Drug R&D through Creative Partnerships |
| 4:35 – 5:00 pm | Jimmy Z. Zhang, Ph.D./MBA, Vice President, Transactions, J&J Innovation, Asia Pacific. New Ways to Source and Fund Innovations |
| 5:00 – 5:30 pm | Platinum and Gold Sponsor Presentations |
| 5:30 – 6:00 pm | Happy Hour |
| 6:00 – 7:00 pm | Dinner |
| 7:00 – 8:30 pm | New Therapeutic Development in China Session chairpersons: Tao Huang and Cheni Kwok |
| 7:00 − 7:20 pm | Chengbin Wu, Ph.D., Chief Scientific Officer and President, Shanghai CP Guojian Pharmaceuticals Co., Ltd. Developing Therapeutic Antibodies in China: Biosimilars and Beyond |
| 7:20 − 7:40 pm | Dechao Yu, Ph.D.,President and CEO, Innovent Biologics, Inc. Innovative Biologics in China: Challenges and Opportunities |
| 7:40 − 8:00 pm | Weidong Jiang, Ph.D., CSO&VP, Henlius Biopharmaceuticals Inc. Antibody therapeutics in China: a challenging pathway |
| 8:00 − 8:20 pm | Lan Huang, Ph.D., Co-Founder & CEO, BeyondSpring Pharmaceuticals, Inc. New US-China Integration Model for Innovative Drug Development for the Global Market |
| 7:50 – 8:30 pm | Group Q & A |
| 8:30 pm | Conference Adjourned |